Axial Shortening in Myopic Children after Repeated Low-Level Red-Light Therapy: Post Hoc Analysis of a Randomized Trial

Introduction Axial length (AL) elongation in myopia is considered irreversible. We aimed to systemically report unexpected AL shortening observed in a randomized clinical trial (RCT) after repeated low-level red-light (RLRL) therapy. Methods This is a post hoc analysis of a multicenter, single-maske...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ophthalmology and Therapy 2023-04, Vol.12 (2), p.1223-1237
Hauptverfasser: Wang, Wei, Jiang, Yu, Zhu, Zhuoting, Zhang, Shiran, Xuan, Meng, Tan, Xingping, Kong, Xiangbin, Zhong, Hui, Bulloch, Gabriella, Xiong, Ruilin, Yuan, Yixiong, Chen, Yanping, Zhang, Jian, Zeng, Junwen, Morgan, Ian G., He, Mingguang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction Axial length (AL) elongation in myopia is considered irreversible. We aimed to systemically report unexpected AL shortening observed in a randomized clinical trial (RCT) after repeated low-level red-light (RLRL) therapy. Methods This is a post hoc analysis of a multicenter, single-masked RCT. Two hundred sixty-four myopic children aged 8–13 years allocated to RLRL treatment (intervention group) or a single vision spectacle (SVS, control group) were included. AL was measured using an IOL-master 500 at baseline, 1-, 3-, 6-, and 12-month follow-up visits. AL shortening was defined as AL reduction from baseline to follow-up visits at three cutoffs: > 0.05 mm, > 0.10 mm, and > 0.20 mm. Frequency of AL shortening at different cutoffs was calculated. Analysis was done with intent to treat (ITT). Results At 12-months follow up, frequency of AL shortening > 0.05 mm was 26/119 (21.85%) and 2/145 (1.38%) for the RLRL group versus the control group, respectively. The frequency was 18/119 (15.13%) versus 0/145 (0%) for AL shortening > 0.10 mm, and 7/119 (5.88%) versus 0/145 (0%), for AL shortening > 0.20 mm, respectively ( p   0.05 mm AL shortening following 12 months of RLRL therapy, whereas AL shortening rarely occurred among controls. Trial Registration ClinicalTrials.gov (NCT04073238).
ISSN:2193-8245
2193-6528
DOI:10.1007/s40123-023-00671-7